Moran Wealth Management LLC Has $1.88 Million Position in DexCom, Inc. $DXCM

Moran Wealth Management LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 84.5% in the first quarter, Holdings Channel reports. The institutional investor owned 29,976 shares of the medical device company’s stock after selling 164,029 shares during the period. Moran Wealth Management LLC’s holdings in DexCom were worth $1,882,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in DXCM. Reflection Asset Management bought a new stake in DexCom during the 4th quarter worth approximately $25,000. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. MCF Advisors LLC bought a new position in shares of DexCom during the fourth quarter valued at $32,000. ORG Partners LLC lifted its holdings in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. Finally, DV Equities LLC acquired a new position in shares of DexCom during the fourth quarter worth $36,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $71.25 on Monday. The firm’s fifty day simple moving average is $68.31 and its two-hundred day simple moving average is $68.19. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a market capitalization of $27.49 billion, a P/E ratio of 30.45, a price-to-earnings-growth ratio of 1.17 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider directly owned 382,482 shares in the company, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,694 shares of company stock worth $3,343,977 over the last three months. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Citigroup restated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price on the stock. UBS Group set a $95.00 price target on DexCom in a research report on Wednesday, June 10th. Benchmark reiterated a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Finally, Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research note on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $84.88.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.